ArticleGenome integrity2010
Low levels of ATM in breast cancer patients with clinical radiosensitivity.
Article in Genome integrity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Individual Radiosensitivity as a Risk Factor for the Radiation-Induced Acute Radiodermatitis.Life (Basel, Switzerland) · 2021Article
- Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?Breast cancer (Dove Medical Press) · 2021Review
- Severe reaction to radiotherapy provoked by hypomorphic germline mutations in ATM (ataxia-telangiectasia mutated gene).Molecular genetics & genomic medicine · 2020Article
- Ataxia-telangiectasia gene (Current oncology (Toronto, Ont.) · 2018Review
- Article
- Non-homologous end-joining protein expression screen from radiosensitive cancer patients yields a novel DNA double strand break repair phenotype.Annals of translational medicine · 2017Article
- WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.Cell research · 2017Article
- Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity.Cancer letters · 2016Article
- 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.BMC cancer · 2016Article
- DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.Biomolecules · 2015Review
- Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.Cell cycle (Georgetown, Tex.) · 2015Article
- ATM gene mutations in sporadic breast cancer patients from Brazil.SpringerPlus · 2015Article
- DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.Radiation and environmental biophysics · 2014Article
- Rho GTPase independent regulation of ATM activation and cell survival by the RhoGEF Net1A.Cell cycle (Georgetown, Tex.) · 2014Article
- Tumor protein D52 represents a negative regulator of ATM protein levels.Cell cycle (Georgetown, Tex.) · 2013Article
- Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.The Journal of biological chemistry · 2012Article
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.EMBO molecular medicine · 2012Article
- Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia.British journal of cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAdjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM gene mutations with these pathologies has been well documented, however, there is uncertainty regarding pathological thresholds for the ATM protein.
resultsSemi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor controls.
conclusionsATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity. From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical radiosensitivity for breast cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.